Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Active not recruiting 4Terminated 1

Sponsor Class

NIH 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 4Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Advanced Breast Carcinoma 1

Interventions

pembrolizumab 98Specimen Handling 79Magnetic Resonance Spectroscopy 70Carboplatin 59Cisplatin 57Biopsy 56Nivolumab 55Radiotherapy 48Cyclophosphamide 46Paclitaxel 44Radiation 37durvalumab 34Dexamethasone 33olaparib 31Gemcitabine 31Etoposide 29Doxorubicin 29atezolizumab 27Rituximab 26Docetaxel 26Taxes 25Ipilimumab 25Bevacizumab 25Vincristine 24Lenalidomide 23Cytarabine 23Prednisone 22Platinum 22Pemetrexed 22X-Rays 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × exemestane × 90 days × Clear all
NCT00310180 2026-06-15

TAILORx

National Cancer Institute (NCI)

Phase 3 Active not recruiting
10,273 enrolled 14 charts
Breast

Breast Neoplasms

NCT01272037 2026-06-15

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
5,018 enrolled 14 charts
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT02115282 2026-05-29

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

National Cancer Institute (NCI)

Phase 3 Active not recruiting
608 enrolled 18 charts
Breast

Breast Neoplasms

NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

NCT06630325 2026-04-28

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
6 enrolled 3 charts
GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡